← All trials
NCT03662022
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2019
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 144000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institute of Tropical Medicine, BelgiumLead sponsor
- Damien Foundation BangladeshOverall official - principal investigator
- Damien Foundation BangladeshCollaborator
- Leiden UniversityCollaborator
- Centre d’Infectiologie Charles MérieuxCollaborator
- Fondation Raoul FollereauOverall official - principal investigator
- GenoscreenCollaborator
- Institute of Tropical Medicine, BelgiumStudy chair
- Institute of Tropical Medicine, BelgiumStudy director
- Instituto de Medicina Integral Professor Fernando FigueiraCollaborator
- L'Institut National de la Santé et de la Recherche MédicaleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.